SEHK:3692Pharmaceuticals
Hansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?
Hansoh Pharmaceutical Group (SEHK:3692) has received approval from China's National Medical Products Administration to start clinical trials of its HS-20136-2 injection for type 2 diabetes and obesity, drawing fresh attention to the stock.
See our latest analysis for Hansoh Pharmaceutical Group.
The clinical trial approval arrives after a sharp swing in sentiment, with Hansoh Pharmaceutical Group’s share price up 17.59% over the past week and 13.09% over 30 days, even though the 90 day share...